MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
Lannett Company Operating Income 2011-2026 | LCI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Lannett Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -176 M | -237 M | 19.6 M | -262 M | 130 M | 86.4 M | 131 M | 226 M | 88.1 M | 18.8 M | 6.91 M | -1.18 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 226 M | -262 M | 2.47 M |
Quarterly Operating Income Lannett Company
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -86.7 M | -14.8 M | -13 M | -27.8 M | -22.1 M | -68.1 M | -8.15 M | -76.2 M | 2.85 M | -217 M | -15 K | -217 M | -15 K | 16.8 M | 9.4 M | 16.8 M | 9.4 M | 36.7 M | -342 M | 36.7 M | -342 M | 47.1 M | 40.7 M | 47.1 M | 40.7 M | 34.3 M | -20.3 M | 34.3 M | -20.3 M | 30.3 M | 51.4 M | 30.3 M | 51.4 M | 66.5 M | 54.7 M | 66.5 M | 54.7 M | 25.4 M | -10.6 M | 25.4 M | -10.6 M | 4.69 M | 3.69 M | 4.69 M | 3.69 M | 495 K | 1.44 M | 495 K | 1.45 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 66.5 M | -342 M | -13.2 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 18.79 | 0.99 % | $ 120 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.12 | 1.63 % | $ 43.9 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.4 | 2.57 % | $ 1.97 B | Canada |
 |
Harrow Health
HROW
|
30.5 M | $ 36.41 | 2.75 % | $ 1.34 B | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.45 | 2.38 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.02 | 3.25 % | $ 110 M | Canada |
 |
PetIQ
PETQ
|
37.1 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.47 | 9.38 % | $ 325 M | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 4.13 | 1.23 % | $ 266 M | USA |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.41 | 2.55 % | $ 402 M | Canada |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.34 | 5.97 % | $ 427 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 23.17 | 2.84 % | $ 1.07 B | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.37 | 4.2 % | $ 3.37 M | Canada |
 |
Tilray
TLRY
|
-1.37 B | $ 6.8 | 5.19 % | $ 4.2 B | Canada |
 |
Solid Biosciences
SLDB
|
-179 M | $ 7.92 | 2.33 % | $ 693 M | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.54 | 2.42 % | $ 343 M | USA |
 |
Viatris
VTRS
|
766 M | $ 13.63 | 3.57 % | $ 16.4 B | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.71 | 1.83 % | $ 3.06 M | USA |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 6.9 | 2.22 % | $ 272 M | USA |
 |
Rockwell Medical
RMTI
|
-4.69 M | $ 0.94 | -0.61 % | $ 33.8 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 2.31 | 4.52 % | $ 2.87 M | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 0.95 | -0.77 % | $ 47.4 M | USA |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.24 M | $ 0.61 | 0.11 % | $ 2.62 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.39 M | $ 2.13 | 5.69 % | $ 24.6 M | USA |